Early Access to Investigational Therapy
Early Access to Investigational Therapy | Astellas Pharma US, Inc.
Astellas believes the safest and most effective way of providing access to our investigational therapies is through enrollment in our ongoing clinical trials.
Early Access Programs - Biogen
Early access is a potential pathway for patients diagnosed with a serious and/or life-threatening disease or condition to gain access to an investigational ...
Our early access program makes our investigational therapies available to qualified patients with critical and compelling need.
Early access programs: Benefits, challenges, and key ...
EAPs offer ethical, compliant, and controlled mechanisms of access to investigational drugs outside of the clinical trial space and before the commercial ...
Early Access Care - Connecting Patients with Investigational ...
Early Access Care connects patients with serious medical conditions to investigational medicinal products when all treatments are exhausted. Learn more!
Position on Early Access and Post-Trial Access to Investigational ...
1 Enrollment in clinical trials is the most effective way to access investigational. Astellas therapies before they are approved in a country.
Early Access Programs – What to Consider as a Patient - WEP Clinical
At this time, clinical trials are still considered the safest option for patients when using investigational drugs, as treatment is provided in a highly ...
Early access programs are a means by which investigational therapies are made available, in certain circumstances, to treat patients with serious diseases.
Access to Investigational Therapies l Exelixis
Requests for investigational medicines, which are medications that have not received regulatory approval, are called “early access” requests. Clinical trials ...
Early Access | Sage Therapeutics
The investigational medicine is currently being studied, or has been studied, in clinical trials for the treatment of a disease or condition that is similar in ...
Providing the investigational medical product will not interfere with investigational trials that could support a medical product's development ...
Early Access Policy - Shionogi Inc.
As this investigational drug is in an early stage of development, we believe it is in the best interest of patients to make it available only through clinical ...
Other Types of Access - Genentech
Early Access Programs ... If a patient is unable to gain access to an unapproved or investigational medicine through a clinical trial, they may be able to gain ...
Pre-approval access to investigational medicines
Then, consideration must be paid to the possibility of a benefit for the patient based on what we know about the investigational medicine at the ...
Information on pre-approval access - argenx
We consider making pre-approval access available to provide investigational therapies for patients diagnosed with a serious or life-threatening disease or ...
Empowering Early Access to Investigational Medical Products
Enabling early access to investigational medical products. Our team's 30-year journey and expertise support patients in need. Learn more about Early Access ...
Patient Access to Investigational Medicines - AnHeart Therapeutics
If a patient is not eligible for an investigational medicine through a clinical trial, they may be able to access an investigational medicine via an early ...
Early Access Programs - EarlyHealth Group
Early access programs (EAPs) are initiatives that provide patients with access to investigational therapies before they become commercially available.
Expanded Access Policy - Ionis Pharmaceuticals
The best way to access an investigational medicine, i.e., a medicine being studied that has not received regulatory marketing approval, is through participation ...
AstraZeneca's Position on Early & Post-Trial Access to Medicines
We understand that there are some circumstances where patients around the world with serious or life-threatening conditions, and for whom other treatment ...